Co-Authors
This is a "connection" page, showing publications co-authored by William Vandergrift and Scott Lindhorst.
Connection Strength
0.294
-
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.
Score: 0.047
-
In?Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. Cancer Invest. 2020 Jul; 38(6):349-355.
Score: 0.046
-
Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 12; 82(6):945-952.
Score: 0.041
-
RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016 Jun; 37(6):7525-34.
Score: 0.034
-
Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma. Cancer Growth Metastasis. 2015; 8:51-60.
Score: 0.034
-
A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/?-catenin signaling pathway. Tumour Biol. 2015 Sep; 36(9):7027-34.
Score: 0.032
-
Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015 Feb; 35(2):615-25.
Score: 0.032
-
Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg. 2014 Apr 05; 1(1).
Score: 0.030